ALZCUR — AlzeCure Pharma AB Income Statement
0.000.00%
- SEK203.96m
- SEK172.46m
Annual income statement for AlzeCure Pharma AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 71.6 | 77.9 | 56.4 | 38.3 | 36.1 |
Operating Profit | -71.6 | -77.9 | -56.4 | -38.3 | -36.1 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -71.4 | -77.8 | -56.2 | -37.2 | -35.2 |
Net Income After Taxes | -71.4 | -77.8 | -56.2 | -37.2 | -35.2 |
Net Income Before Extraordinary Items | |||||
Net Income | -71.4 | -77.8 | -56.2 | -37.2 | -35.2 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -71.4 | -77.8 | -56.2 | -37.2 | -35.2 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1.71 | -1.87 | -1.11 | -0.565 | -0.457 |
Dividends per Share |